SMO and myelodysplastic syndrome: As a SMO antagonist, Glasdegib, an oral inhibitor of the Hedgehog signalling pathway, has been developed in clinical trials [95] in combination with standard chemotherapy for patients with AML or high-risk MDS [96, 97].